Elecoglipron, an oral pill in the same drug class as Ozempic and Wegovy, lowered blood sugar and body weight in a phase 2b type 2 diabetes trial, and unlike the existing oral option, it does not need to be taken on an empty stomach.
A pill in the same drug class as Ozempic and Wegovy has cleared a mid-stage test in type 2 diabetes, and the version that matters is the one that does not need to be taken on an empty stomach.
The class is called GLP-1 receptor agonists, and it is the chemistry behind the best-selling injectable diabetes and obesity drugs of the past five years. Most of these medications are injections because the active molecules are peptides, which are fragile in the stomach and hard to deliver as pills. The one oral GLP-1 already on the market, a pill form of semaglutide sold as Rybelsus for type 2 diabetes, only works if patients take it on an empty stomach and wait before eating or drinking, a constraint that has limited its uptake.
A new pill called elecoglipron is designed to sidestep both frictions. In a phase 2b trial called SOLSTICE, presented at the American Diabetes Association Scientific Sessions and published in The Lancet, the once-daily pill lowered HbA1c, the standard measure of long-term blood sugar, and reduced body weight in adults with type 2 diabetes compared with placebo, according to a summary of the data on ScienceDaily. The investigator presenting the data, Vanita Aroda of Mass General Brigham, framed the result as a step toward a simpler option for the kind of patient most likely to be prescribed a diabetes drug in primary care.
The structural difference is the chemistry. Elecoglipron is a non-peptide small molecule, which means it is a stable, orally available compound that does not need the absorption-boosting formulation tricks that oral semaglutide relies on. In principle, that lets the pill be taken at any time of day, stored at room temperature, and manufactured at a lower cost per dose. Non-peptide oral GLP-1s are now a small wave rather than a single product, and elecoglipron is the second entrant to post mid-stage data, with orforglipron further along in late-stage testing.
The caveats are real. SOLSTICE compared elecoglipron to placebo, not to injectable semaglutide or tirzepatide, so any claim that the new pill "matches" the injectables is a cross-trial comparison at best. The trial was a phase 2b dose-finding study, which is long enough to read out glycemic effect but too short for cardiovascular outcomes, durability of weight loss, or the rarer gastrointestinal side effects that have dogged the class. The press materials distributed so far do not name a sponsor or disclose pricing, so the corporate and commercial story behind the molecule is incomplete.
For now, the watch items are concrete: a phase 3 program with longer follow-up and head-to-head arms, regulatory filing timing, and whether the pill is positioned first for diabetes, for obesity, or for both. The structural pitch, an oral GLP-1 that drops the needle and drops the fasting rule, is the part of the story that survives the caveats. Whether it survives a phase 3 readout is the part that has to be earned.